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Changes in the Cardiac GHSR1a-Ghrelin
System Correlate With Myocardial
Dysfunction in Diabetic
Cardiomyopathy in Mice
Rebecca Sullivan,1,2 Rebecca McGirr,1 Shirley Hu,3 Alice Tan,2 Derek Wu,2
Carlie Charron,4 Tyler Lalonde,4 Edith Arany,2 Subrata Chakrabarti,2
Leonard Luyt,4,5,6 and Savita Dhanvantari1,2,7
Imaging Research, Lawson Health Research Institute, London, Ontario N6A 4V2, Canada;
Department of Pathology and Laboratory Medicine, Western University, London, Ontario N6A 4V2,
Canada; 3Department of Physiology and Pharmacology, Western University, London, Ontario N6A 3K7,
Canada; 4Department of Chemistry, Western University, London, Ontario N6A 5B7, Canada;
5
Departments of Oncology and Medical Imaging, Western University, London, Ontario N6A 4L6, Canada;
6
London Regional Cancer Program, Lawson Health Research Institute, London, Ontario N6A 4V2,
Canada; and 7Department of Medical Biophysics, Western University, London, Ontario N6A 5C1, Canada

Ghrelin and its receptor, the growth hormone secretagogue receptor 1a (GHSR1a), are present in cardiac
tissue. Activation of GHSR1a by ghrelin promotes cardiomyocyte contractility and survival, and changes
in myocardial GHSR1a and circulating ghrelin track with end-stage heart failure, leading to the hypothesis that GHSR1a is a biomarker for heart failure. We hypothesized that GHSR1a could also be a
biomarker for diabetic cardiomyopathy (DCM). We used two models of streptozotocin (STZ)-induced
DCM: group 1, adult mice treated with 35 mg/kg STZ for 3 days; and group 2, neonatal mice treated with
70 mg/kg STZ at days 2 and 5 after birth. In group 1, mild fasting hyperglycemia (11 mM) was first
detected 8 weeks after the last injection, and in group 2, severe fasting hyperglycemia (20 mM) was first
detected 1 to 3 weeks after the last injection. In group 1, left ventricular function was slightly impaired as
measured by echocardiography, and Western blot analysis showed a significant decrease in myocardial
GHSR1a. In group 2, GHSR1a levels were also decreased as assessed by Cy5-ghrelin(1–19) fluorescence
microscopy, and there was a significant negative correlation between GHSR1a levels and glucose
tolerance. There were significant positive correlations between GHSR1a and ghrelin and between
GHSR1a and sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2a), a marker for contractility, but not
between GHSR1a and B-type natriuretic peptide, a marker for heart failure. We conclude that the
subclinical stage of DCM is accompanied by alterations in the myocardial ghrelin-GHSR1a system,
suggesting the possibility of a biomarker for DCM.
Copyright © 2018 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution NonCommercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-ncnd/4.0/).

Diabetes affects ~6.5% of the population, or 347 million people worldwide, with this number
expected to increase to 7.7%, or 439 million, by 2030 [1]. Cardiovascular disease affects ~80%
of people with diabetes, and it is the major cause of morbidity and mortality. Diabetic cardiomyopathy (DCM) is a specific clinical condition characterized by progressive cardiac
dysfunction without extensive coronary artery disease or hypertension [2]. The early stages of
DCM represent a latent subclinical phase marked by diastolic dysfunction, oxidative stress,
Abbreviations: AUC, area under the curve; BNP, B-type natriuretic peptide; CHF, chronic heart failure; DCM, diabetic cardiomyopathy; EDD, end diastolic diameter; ERK, extracellular signal–related kinase; ESD, end systolic diameter; GHSR, growth
hormone secretagogue receptor; GHSR1a, growth hormone secretagogue receptor 1a; IgG, immunoglobulin G; IPGTT, intraperitoneal
glucose tolerance test; LV, left ventricular; SEM, standard error of the mean; SERCA2a, sarcoplasmic reticulum Ca2+-ATPase 2a; SR,
sarcoplasmic reticulum; STZ, streptozotocin.
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1. Materials and Methods
A. Animals
The Animal Use Subcommittee of the Canadian Council on Animal Care at Western University approved the protocols for all mouse handling and treatment procedures described in
this study (protocols #2012-020 and #2015-097). There were two cohorts of mice in this study.
Cohort 1 consisted of wild-type C57BL/6J female mice obtained from Jackson Laboratories at
5 weeks of age, which were randomly assigned to control (n = 6) or multiple low-dose STZ
treatment (n = 6). Mice were injected intraperitoneally with 50 mg/kg STZ or with vehicle
(sodium citrate buffer) once every other day for 3 days. Blood glucose readings (after a 4-hour
fast) were taken 4 days before the first STZ injection and once per week for 10 weeks after
the last STZ injection with a Bayer Ascensia Breeze 2 glucose meter and strips (Bayer
HealthCare). Intraperitoneal glucose tolerance tests (IPGTTs) were conducted as described
previously [20] 4 days before STZ treatment and 10 weeks after the last STZ injection. Briefly,
fasting blood glucose readings were taken, and all mice were then injected intraperitoneally
with 2 mg/kg of 40% dextrose. Blood glucose readings were taken 5, 25, 30, 60, and 90 minutes
after injection. The area under the curve (AUC) for glucose tolerance tests was calculated with
GraphPad Prism (GraphPad Software, Inc.).
Cohort 2 consisted of male and female nonobese diabetic/severe combined immunodeficient
mice injected twice per day with vehicle (n = 8) or 35 mg/kg STZ (n = 6) at days 2 and 5 after
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derangements in Ca2+ homeostasis, and altered substrate utilization, resulting in myocardial
lipotoxicity [3].
Ghrelin and its receptor, the growth hormone secretagogue receptor 1a (GHSR1a), are new
molecules of interest that may track the progression of heart disease and the cardiomyopathy
of diabetes. Ghrelin is a 28-amino-acid peptide hormone and is posttranslationally modified
on Ser3 by octanoylation, a modification that is critical for binding to GHSR1a [4]. Both the
acylated and nonacylated forms have been found in pericardial fluid [5], indicating that the
human heart produces and secretes both forms. Both ghrelin and GHSR1a are present in
the myocardium [6, 7] and may represent a ghrelin/GHSR1a system independent of the
ghrelin/GHSR1a system that regulates energy expenditure. In myocardial tissue sections
from patients with chronic heart failure (CHF), there were impaired ghrelin production and
elevated GHSR1a levels, demonstrating that the ghrelin/growth hormone secretagogue receptor (GHSR) system is altered in end-stage heart failure [7]. Studies in ghrelin knockout
mice have shown a role for ghrelin in the attenuation of left ventricular (LV) remodeling and
excessive sympathetic activity after myocardial infarction [8, 9]. These cardioprotective effects of ghrelin may be mediated through activation of myocardial GHSR1a, as evidenced
through signaling pathways that inhibit apoptosis [10] and promote angiogenesis (Akt
phosphorylation), survival (adenosine 50 -monophosphate–activated protein kinase), and
proliferation [extracellular signal–related kinase (ERK) phosphorylation] [11]. Activation of
GHSR1a also regulates intracellular Ca2+ levels, and this mechanism may protect cardiomyocytes from ischemia/reperfusion injury [12] and preserve electrophysiological
properties after myocardial infarction, thereby inhibiting apoptosis and promoting cell
survival [13].
Although there is an established connection between myocardial ghrelin/GHSR and heart
function and evidence that activation of ghrelin/GHSR1a signaling can prevent cardiac
dysfunction after myocardial infarction [14, 15] and in CHF [16, 17], little is known about its
expression and role in the progression of DCM. One recent study has shown that that
treatment of diabetic mice with des-acyl ghrelin prevented cardiac dysfunction and cardiac
fibrosis and enhanced signaling through adenosine 50 -monophosphate–activated protein
kinase/ERK 1 and 2 [18]. However, des-acyl ghrelin does not bind GHSR1a [19]. To probe the
relationship between cardiac ghrelin/GHSR and DCM, we examined changes in myocardial
ghrelin and GHSR1a in mice with streptozotocin (STZ)-induced type 1 diabetes.
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birth, as previously described for multiple low-dose STZ administration in neonatal mice [21].
At days 7, 14, 21, and 28 after STZ injection, IPGTTs were conducted after a 4-hour fast. Mice
were euthanized immediately after IPGTT, and hearts were quickly removed, immersionfixed in 4% paraformaldehyde, dehydrated in 30% sucrose (in phosphate-buffered saline), and
snap-frozen in optimal cutting temperature compound for histological analyses. Because
there were no apparent differences in AUC IPGTT values between the different time points,
all STZ-treated mice were pooled into one treatment group.
B. Echocardiography

C. Insulin Measurements and Western Blot Analysis
For determination of circulating insulin levels, trunk blood was collected after euthanasia.
Insulin levels in serum were measured by enzyme-linked immunosorbent assay (Luminex).
Western blot analysis of GHSR1a was conducted as described previously [23], with 50 mg
cardiac protein extract from control and STZ-treated mice. We used 5 mg of GHSR1aexpressing membrane as positive control. Membranes were incubated in anti-GHSR1a
rabbit polyclonal antibody, followed by horseradish peroxidase–linked secondary antibody
(Table 1) for 1 hour. Bands were visualized and quantified with the Chemi Genius Bio
Imaging System (Syngene) and GeneSnap software (Syngene).

Table 1. Information on Primary and Secondary Antibodies Used
Antigen
Ghrelin
SERCA2a
BNP
Alexa Fluor 488
Alexa Fluor 594
GHSR1a
IgG horseradish peroxidase conjugated

Catalog #

Dilution

Host

RRID#

sc-10359
ab3625
ab19645
A11055
A21207
sc20748
ab7090

1:100
1:300
1:1000
1:500
1:500
1:500
1:5000

Goat
Rabbit
Rabbit
Donkey anti-goat
Donkey anti-rabbit
Rabbit
Goat anti-rabbit

AB_2111733
AB_303961
AB_445037
AB_2534102
AB_141637
AB_2232483
AB_955417
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In cohort 1 mice, assessment of LV function was performed by echocardiography. Hair was
removed from the abdominal region with Nair™ hair removal cream (Church & Dwight Co.,
Inc.). Mice were anesthetized with 0.2 mL/20 g body weight of ketamine hydrochloride
(Bioniche) through intraperitoneal injection. Aquasonic 100 ultrasound transmission gel
(Parker Laboratories, Inc.) was applied onto a 15-MHz linear transducer and the abdominal
region of each mouse. Echocardiogram assessments were performed on a VisualSonics
scanner, and images were acquired in M-mode in Vevo 2100 Imaging System Cardiac Package
software (VisualSonics). Papillary muscle was used as a landmark for locating the left
ventricle. Fifteen to 20 images 1.5 to 5 seconds in duration were captured per mouse. A
representative image was selected for each mouse based on the edge clarity of the endocardium, which is the innermost layer of the myocardium. Following a standard protocol [22],
we used measurement tools to determine anterior wall thickness, posterior wall thickness and
LV dimensions in both systole [end systolic diameter (ESD)] and diastole [end diastolic diameter (EDD)] from three consecutive cardiac cycles. Heart rates were averaged over five
cardiac cycles from M-mode images. Ventricular parameters were calculated with the following standard formulas: percentage fractional shortening = [(EDD 2 ESD)/EDD] 3 100; LV
mass = 1.055 * [(anterior wall thickness + EDD + posterior wall thickness)3 2 EDD3], where
1.055 is the specific density of the myocardium; corrected LV mass = (0.8 3 LV mass) + 0.6.
Immediately after the imaging session, mice were euthanized by CO2 overdose, and their
hearts were collected. A small portion of the left ventricle was removed for histological
staining, and the remainder was used for Western blot analysis of GHSR1a.
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D. Immunofluorescence Microscopy

E. Fibrosis Imaging
Heart tissue sections were stained with Masson trichrome stain with picric acid in collaboration with the Pathology Core Laboratory at London Health Sciences Centre. Sections were
visualized with bright field microscopy at 2003 magnification with a Zeiss Axioskop ELEinsatz microscope (Carl Zeiss) and Northern Eclipse software (Empix Imaging Inc.).

2. Results
A. Measurements of Glucose Tolerance and Cardiac Function in Cohort 1 Mice
In adult female C57BL/6 mice treated with multiple low-dose STZ, there was a fourfold
decrease in serum insulin levels (P , 0.001) 72 days after STZ injection. At this same time,
there was a 68% (P , 0.01) increase in blood glucose and a 65% (P , 0.01) increase in AUC
(Table 2), indicating mild fasting hyperglycemia and impaired glucose tolerance. Some parameters of cardiac function, as determined by echocardiography, were altered: there was a
significant increase (P , 0.01) in percentage fractional shortening, the LV mass decreased by
40% (P , 0.05), and the ESD decreased by 27% (P , 0.05) in the STZ-treated mice (Table 3).
Table 2. Body Weights, Insulin, and Glucose Levels for Cohort 1
Body
Serum Insulin Blood Glucose Blood Glucose
Weight (g)
(pg/mL)
d0 (mM)
d72 (mM)
AUC IPGTT d0 AUC IPGTT d72
Control
STZ

23.1 6 0.2
23.3 6 0.2

718 6 60
179 6 17b

8.1 6 0.2
8.4 6 0.3

7.8 6 0.4
11.5 6 0.9a

1090 6 77
1128 6 54

1220 6 54
1864 6 167a

Glucose measurements were taken before (d0) and after (d72) STZ administration of mice in cohort 1. Values are
means 6 SEM (n = 6).
a
P , 0.01.
b
P , 0.001.
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Hearts were frozen and embedded in optimal cutting temperature compound as previously
described [19, 23] and sectioned at 7 mm with a cryostat. Immunofluorescence staining was
conducted as previously described [19, 23], with primary polyclonal antibodies as listed in
Table 1 for 1 hour at room temperature. Samples were rinsed 23 in phosphate-buffered saline
and incubated for 2 hours at room temperature with Alexa Fluor 488 donkey anti-goat
immunoglobulin G (IgG) (Table 1) to visualize ghrelin and the heart failure biomarker B-type
natriuretic peptide (BNP), and Alexa Fluor 594 donkey anti-rabbit IgG (Thermo Fisher
Scientific) (Table 1) to visualize sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2a), a
sarcoplasmic reticulum (SR) protein that regulates intracellular Ca2+ flux. GHSR1a was
detected with a far-red ghrelin analog probe ([Dpr3(octanoyl),Lys19(Cy5)ghrelin (1–19)amide, referred to for simplicity as Cy5-ghrelin(1–19)] for 30 minutes, as previously reported
[19]. We have shown that this fluorescently labeled ghrelin peptide analog binds to GHSR1a
with similar affinity to that of wild-type ghrelin and can be used to detect changes in GHSR1a
[19]. Sections were washed and mounted with ProLong Gold Antifade (Life Technologies).
Images were captured on a Nikon Eclipse TE2000-S fluorescent microscope. Five random
fields of view were acquired for each of four sections per heart at 203 magnification (Nikon
NIS Elements version BR 4.50.00; Nikon Instruments). Images were imported for analysis
into FIJI version 1.49v, a distribution of ImageJ (National Institutes of Health). Fluorescence
was quantified with a custom FIJI script that returns raw integrated density, representing
protein expression levels, as previously reported [19, 24]. Data analyses were performed with
an unpaired Student t test, a one-way analysis of variance with Tukey post hoc test, and
Pearson correlation with significance set at P , 0.05.
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Table 3. Echocardiographic Measurements for Cohort 1

Heart rate, bpm
Anterior wall thickness, mm
Posterior wall thickness, mm
LV EDD, mm
LV ESD, mm
LV mass, corrected, mg
Fractional shortening, %

Control

STZ

326 6 13
0.9 6 0.05
0.8 6 0.1
3.5 6 0.2
2.8 6 0.2
70.5 6 5.7
21.7 6 1.1

287 6 26
0.9 6 0.2
0.8 6 0.1
3.2 6 0.2
2.2 6 0.2a
50.5 6 5.7a
32.6 6 2.6b

There were no differences in the heart rate, the anterior or posterior wall thickness, or the
EDD (Table 3). Therefore, these mice showed some changes in LV function that were concomitant with mild fasting hyperglycemia and impaired glucose tolerance after treatment
with STZ.
B. Expression of Cardiac GHSR1a in STZ-Treated Mice
Myocardial GHSR1a was assessed through Western blot analysis with the excised hearts of
mice in cohort 1. Western blot analysis showed distinct bands corresponding to the molecular
weight of GHSR1a (44 kDa) and cardiac troponin I (24 kDa), used as a positive control (Fig.
1A). A 2.6-fold (P , 0.05) decrease of GHSR1a (Fig. 1B) was seen in mice treated with STZ.
C. Presence of Cardiac Fibrosis in Mouse Heart Tissues
The extent of cardiac fibrosis was detected in the hearts of mice in cohort 1 with histology and
Masson trichrome stain. Representative images (Fig. 2A, 2B) show no apparent changes in
the amounts of fibrotic tissue (blue) compared with the healthy tissue (red) in the STZ-treated
mice vs. the control mice.
D. Glucose Tolerance of High-Dose STZ-Treated Mice
Neonatal mice from cohort 2 were treated with multiple low-dose STZ (35 mg/kg twice per day
on day 2 and day 5 after birth) to induce diabetes in an acute manner. Body weights, blood

Figure 1. Changes in levels of myocardial GHSR1a in STZ-induced diabetes in cohort 1.
(A) Western blot analysis of GHSR1a in control and STZ-treated mice with cardiac troponin
as control. (B) Quantification of Western blot analysis, where data are represented as
densitometric ratios of GHSR1a to cardiac troponin. Data are expressed as mean 6 standard
error of the mean (SEM) (n = 6). *P , 0.05.
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Echocardiograph measurements were conducted 16 weeks after STZ injection before time of euthanasia in cohort 1.
Values are means 6 SEM (n = 6).
a
P , 0.05.
b
P , 0.01.
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glucose, and the AUC were measured before euthanasia (Table 4). The body weights of STZtreated mice were not significantly different when compared with those of control mice.
Fasting blood glucose levels increased 2.9-fold (P , 0.01) in the mice treated with STZ, and the
AUC increased 4.2-fold (P , 0.0001).
E. Quantitative Fluorescence Microscopy of GHSR1a, Ghrelin, and Other Metabolic Markers of
Heart Function
The expression of GHSR1a and other metabolic markers were measured in cardiac tissue
sections from cohort 2. We have previously characterized Cy5-ghrelin(1–19) for its binding to
and quantification of GHSR1a in situ [19]. Here, Cy5-ghrelin(1–19) was used to quantify the
expression of GHSR1a, and immunofluorescent microscopy was used to determine the expression of ghrelin, BNP, and SERCA2a. BNP is a known biomarker for heart failure [25, 26],
and SERCA2a regulates Ca2+ flux from the SR and is altered in diabetes [27]. Representative
images of heart tissue from control (Fig. 3A–3D) and STZ-treated mice (Fig. 3E–3H) qualitatively show a decrease in the expression of GHSR1a and SERCA2a. Quantification of the
fluorescent images (Fig. 3I) shows a 63% (P = 0.0042) decrease in expression of GHSR1a and
an 85% (P = 0.0015) decrease in SERCA2a levels in hearts of diabetic mice. There was no
difference in BNP or ghrelin expression between the control and STZ-treated mice.
F. Correlations Between GHSR1a, Ghrelin, BNP, and SERCA2a Expression in Mouse
Cardiac Tissue
The quantified fluorescent data were used to determine possible relationships between the
metabolic markers and glucose tolerance (AUC). There were significant negative correlations
between AUC and GHSR1a (r = 0.6632, P = 0.0097) and AUC with SERCA2a (r = 0.6508, P =
0.0117) (Fig. 4). There were no significant correlations between AUC and ghrelin or BNP.
Table 4. Body Weights, AUC, and Glucose Levels for Cohort 2

Control
STZ

Body Weight (g)

Blood Glucose After STZ (mM)

AUC IPGTT After STZ

21.7 6 0.7
18.5 6 1.5

6.8 6 0.5
19.7 6 3.2a

890.2 6 64
3745 6 87b

=Glucose measurements were taken 1 to 4 weeks after STZ administration of mice in cohort 2. Values are means 6
SEM (n = 8 control, n = 6 STZ).
a
P , 0.01.
b
P , 0.0001.
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Figure 2. Cardiac fibrosis in (A) control and (B) STZ-treated mice from cohort 1. Representative
images where blue is increased collagen deposition and red is healthy cardiac tissue.
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Additional analysis examined relationships between metabolic markers. Interestingly,
there was a highly significant positive correlation (r = 0.7575, P = 0.0017) between GHSR1a
and ghrelin (Fig. 5A) and also between GHSR1a and SERCA2a (r = 0.7154, P = 0.0040) (Fig.
5C). In contrast, there was no significant interaction between GHSR1a and BNP (Fig. 5B).
Interestingly, ghrelin and SERCA2a (Fig. 5D) also showed a strong positive correlation (r =
0.8185, P = 0.0003).
G. Presence of Cardiac Fibrosis in Mouse Heart Tissues
As for cohort 1, cardiac fibrosis was measured in cohort 2 via histology (Masson trichrome
stain). Representative images (Fig. 6A, 6B) show no differences in the amount of fibrotic tissue
(blue) compared with the healthy heart tissue (red) in the STZ-treated mice.

3. Discussion
In mouse models of type 1 diabetes, there is considerable evidence of cardiac dysfunction. In
particular, in the STZ-induced mouse model, there are marked alterations in contractile
function, accompanied by changes in cardiomyocyte Ca2+ homeostasis, increased oxidative
stress, and altered substrate metabolism [28]. It is known that GHSR and ghrelin are
expressed in the myocardium, and the expressions of both change in heart failure in humans
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Figure 3. Fluorescence microscopy analysis of GHSR1a, ghrelin, BNP, and SERCA2a in
control and STZ-treated mice. Representative fluorescent images in cohort 2 of (A to D)
control and (E to H) STZ-treated mice for GHSR1a, ghrelin, BNP, and SERCA2a. (I) Images
were quantified as described in Materials and Methods. There were significant differences
between control and STZ-treated mice in levels of GHSR1a and SERCA2a. Data are
expressed as mean 6 SEM based on independent t tests with significance set at P , 0.05.
**P , 0.01.
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[7]. In this study, we examined changes in levels of GHSR1a, along with changes in cardiac
function or with known markers of DCM in mouse models of type 1 diabetes. Our major
findings are that in both a chronic mild and an acute severe phenotype of type 1 diabetes,
myocardial GHSR1a levels decreased before development of fibrosis. In the chronic, mild
diabetic phenotype, the decrease in cardiac GHSR1a was accompanied by slight impairments
in LV function. In the acute, severe diabetic phenotype, the decrease in GHSR1a did not
correlate with a known marker of heart failure, BNP [25, 26]. However, levels of both GHSR1a
and its ligand, ghrelin, did positively correlate with levels of SERCA2a, a marker of
excitation-contraction coupling in cardiomyocytes. These results indicate that changes in
GHSR1a expression may indicate changes in cardiac contractile function that characterize
the subclinical phase of DCM.
The STZ-treated mouse has long been used as a model to study the progression and
treatment of DCM [28]. Although high doses of STZ may induce effects on cardiomyocyte
contraction independently of diabetes [29], administering STZ in multiple lower doses, as we
did, may help avoid such effects. The multiple low-dose STZ model is attractive because of its
ease of administration and the ability to induce diabetes quickly in different strains in both
adult and neonatal mice, as we have done in the current study. As the current study and other
studies [30] have shown, the STZ-treated mouse shows mild changes in LV function as
measured by echocardiography, and there is very little indication that BNP, a marker of heart
failure, or collagen type 1, a marker of fibrosis, are elevated. Instead, many changes occur in
the biochemical pathways that lead to the development of DCM, such as increases in lipid
oxidation, loss of contractility, and alterations in intracellular Ca2+ handling [28]. Therefore,
it is an excellent model to study the subclinical changes that may precede overt DCM.
However, it is possible that the changes in myocardial GHSR1a that we observed in cohort
1 reflect a level of cardiac inflammation as a result of STZ administration. A recent report
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Figure 4. Correlation of GHSR, ghrelin, and BNP fluorescence intensities with glucose
tolerance. Linear regression of ghrelin (green), GHSR1a (red), BNP (blue), and SERCA2a
(gray) between the AUC and the raw integrated density. Each dot represents an individual
animal, including both the control and the STZ-treated mice. There were significant negative
correlations with glucose tolerance and GHSR1a (P = 0.0097, r2 = 0.6632) and SERCA2a
(P = 0.0117, r2 = 0.6508) but not with ghrelin (P = 0.0921, r2 = 0.4672) or BNP (P = 0.8324,
r2 = 0.2548).
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showed that multiple low-dose administration of STZ in adult male C57BL/6 mice upregulated markers of myocardial inflammation in the heart, including tumor necrosis factor-a,
interleukin-6, interleukin-1b, and monocyte chemotactic protein-1, which coincided with
increased cardiac fibrosis [31]. In contrast, we did not detect any appreciable fibrosis, indicating
that it is unlikely that chronic inflammation was present. Nonetheless, we cannot rule out the

Figure 6. Cardiac fibrosis in (A) control and (B) STZ-treated mice from cohort 2.
Representative images where blue is increased collagen deposition and red is healthy
cardiac tissue.
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Figure 5. Correlational analyses of GHSR, ghrelin, BNP, and SERCA2a fluorescence
intensities. Each point represents an individual mouse from either the control or STZ-treated
group in cohort 2. There were significant interactions between (A) ghrelin and GHSR1a, (C)
SERCA2a and GHSR1a, and (D) ghrelin and SERCA2a, but there was no significant
correlation between (B) BNP and GHSR1a.
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possibility that there may be a very low level of inflammation preceding the onset of fibrosis and
that changes in GHSR1a levels may be caused by such subclinical inflammation.
The primary significant correlation that was obvious from our study is that between both
ghrelin and GHSR1a and SERCA2a, an SR membrane protein that transports intracellular
Ca2+ into the SR during cardiomyocyte relaxation. The strong positive correlation suggests
that GHSR1a activation by ghrelin may function to regulate cardiomyocyte contractility through control of Ca2+ flux from the SR. Evidence of a role for ghrelin in controlling
Ca2+ flux through modulation of ion channels was shown in studies where ghrelin was
administered to ventricular myocytes isolated from adult male rats [32]. Treatment with
ghrelin increased the amplitude of the Ca2+ current through L-type voltage-gated Ca2+
channels, which was associated with increased cardiomyocyte contractility. However,
whether ghrelin and GHSR1a also control Ca2+ flux at the level of the SR remains to be
elucidated. This type of mechanism is especially pertinent to the progression of DCM; in
diabetic rat hearts, decreased SERCA2a results in insufficient sequestration of Ca2+ in the
SR, leading to impaired relaxation that characterizes the diastolic dysfunction of early DCM
[27]. Conversely, overexpression of SERCA2a attenuates contractile dysfunction in STZtreated mice [33]. Therefore, SERCA2a, and the associated proteins that control Ca2+ flux in
the SR, are key regulators of myocardial contractility in DCM, and the ghrelin/GHSR
system may be a biomarker for this mechanism.
The onset of cardiomyopathy has also been well characterized in the male Akita mouse
model (Ins2WT/C96Y) of type 1 diabetes. In 3- and 6-month-old male Akita mice, there were no
discernable changes in the LV echocardiographic parameters (ejection fraction, percentage
fractional shortening, EDD or ESD); however, Doppler imaging showed early diastolic
dysfunction with preserved systolic function [34]. These changes were accompanied by decreases in the levels of the signaling molecules Akt, ERK ½, and SERCA2a at 6 months of age,
but there was no evidence of fibrosis. These effects were attributed to impaired signaling
through the insulin receptor. Interestingly, both Akt and ERK 1/2 are also associated with
cardiac GHSR1a signaling [10, 12], so it is likely that decreases in GHSR1a could also drive
the reported decreases in phosphorylated Akt.
There may be a role for ghrelin as a possible biomarker for heart failure. In a study
involving 145 patients with CHF, serum levels of ghrelin were significantly lower in
patients with severe heart failure, and prognosis improved as serum ghrelin levels increased. Also, survival could be predicted based on a serum ghrelin level of .85 pM [35].
However, in DCM, serum ghrelin levels could be confounded by its role in energy balance.
Plasma ghrelin levels increase dramatically in models of type 1 diabetes and can be
suppressed by leptin infusion [36]. It is not known what effect these elevated circulating
ghrelin levels would have on cardiac function and metabolism. Assuming that circulating
ghrelin levels are elevated in our models, there could be negative feedback regulation of
myocardial GHSR1a by circulating ghrelin. However, there is an intriguing possibility
that the cardiac GHSR1a/ghrelin system functions independently of circulating ghrelin,
because our results also show a decrease in the downstream signaling molecule, SERCA2a. These results suggest that myocardial GHSR1a is not activated in the face of high
plasma ghrelin and instead may respond to autocrine activation. We are currently investigating this possibility.
Our results seem to indicate that cardiac tissue levels of ghrelin, together with GHSR1a,
may be more appropriate markers of early cardiac dysfunction and may indicate changes in
intracellular Ca2+ homeostasis in cardiomyocytes. Although we showed that a decrease in
myocardial GHSR1a indicated the severity of impairment in glucose tolerance, a study involving tissue biopsies from 12 patients with CHF showed that both immunoreactive GHSR1a
and GHSR1 AMRNA levels were dramatically increased in patients with end-stage heart
failure [7]. Therefore, it appears that myocardial GHSR1a levels are altered differently in
early-onset DCM and in end-stage heart failure. We are currently investigating a role for
cardiac ghrelin and GHSR1a as an integrated system biomarker for the onset of DCM and
heart failure.
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